en · de · es · fr · pt
hplc-notes.peptides4088.com › Topic › Molecular Identity Of Thymosin Alpha-1 — Background and Details

Molecular Identity Of Thymosin Alpha-1 — Background and Details

By Editorial Desk · published 2025-10-17 · last reviewed 2025-12-04 · Topic

Immunomodulatory peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.

Molecular Identity Of Thymosin Alpha-1

Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.

Molecular Background and Immune Action

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Thymosin-alpha-1 at a glance

PropertyValueNotes
ClassSynthetic peptide28 residues; not a small-molecule compound
Molecular massAbout 3,106 DaMonoisotopic mass of the unmodified chain
N-terminal groupAcetylated serinePresent in both native and synthetic forms
Secondary structureDisulfide-constrained loopOne bridge between two cysteine residues
Typical sourceSolid-phase synthesisEarly isolates came from bovine thymus extracts

Molecular Background and Identity

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.

Related pages on this site

Background, Structure, and Mechanism

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Handling, Storage, and Analytical Verification

Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.

Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.

Notes from published material

As the name for the element of atomic number 96 we should like to propose "curium", with symbol Cm. The evidence indicates that element 96 contains seven 5f electrons and is thus analogous to the element gadolinium, with its seven 4f electrons in the regular rare earth series. On this basis element 96 is named after the Curies in a manner analogous to the naming of gadolinium, in which the chemist Gadolin was honored. The first curium samples were barely visible, and were identified by their radioactivity. Louis Werner and Isadore Perlman made the first substantial sample of 30 μg curium-242 hydroxide at University of California, Berkeley in 1947 by bombarding americium-241 with neutrons. Macroscopic amounts of curium(III) fluoride were obtained in 1950 by W. W. T. Crane, J. C. Wallmann and B. B. Cunningham. Its magnetic susceptibility was very close to that of GdF3 providing the first experimental evidence for the +3 valence of curium in its compounds. Curium metal was produced only in 1950 by reduction of CmF3 with barium.

=== Lawsuits === In September 2009, the U.S. Justice Department announced that Pfizer had been ordered to pay a historic fine of $2.3 billion as a penalty for fraudulent marketing of several drugs, including Geodon. Matthew Dougherty, a 51‑year‑old former teacher and artist with a diagnosis of schizophrenia, died on May 21, 2024, at Phoenixville Hospital in Phoenixville, Pennsylvania. According to a wrongful death lawsuit filed by his family in March 2025, Dougherty had been admitted to the hospital after a mental health crisis during which he was tased by police and suffered injuries. While hospitalized, Dougherty's regular psychiatric medications were discontinued. On the evening of his death, an alarm sounded in a nearby room, causing him to become agitated. Hospital staff called the police to restrain him, and responding officers again used a taser on Dougherty. Shortly afterward, nurses administered two doses of Geodon (ziprasidone) – a total of 40 mg, an amount the lawsuit equated to "administering poison". Minutes later, Dougherty went into cardiac arrest and could not be resuscitated. The lawsuit names as defendants Tower Health, which operates Phoenixville Hospital, and seeks damages for wrongful death and negligence. At the time the suit was filed, Tower Health had not filed a response to the complaint.

There are several Akabori amino acid reactions, which are named after Shirō Akabori (Japanese: 赤堀 四郎) (1900–1992), a Japanese chemist. In the first reaction, an α-amino acid is oxidised and undergoes decarboxylation to give an aldehyde at the former α position by heating with oxygen in the presence of a reducing sugar. This reaction is useful for preparing dichlorophthalimido derivatives of peptides for mass spectral analysis.

On April 9, 1953, Giáp, after having failed repeatedly in direct attacks on French positions in Vietnam, changed strategy and began to pressure the French by invading Laos, surrounding and defeating several French outposts such as Muong Khoua. In May, General Henri Navarre replaced Salan as supreme commander of French forces in Indochina. He reported to the French government "... that there was no possibility of winning the war in Indo-China", saying that the best the French could hope for was a stalemate. Through the Navarre Plan, French forces and the Vietnamese National Army sought to use their advantage in technology and arms to hold cities and key roads, thereby hoping to force the Việt Minh into an impasse and negotiation. Per this strategy, French forces fortified the town of Điện Biên Phủ in an effort to block the Việt Minh's connections with Laos and Việt Minh bases there. The town was located along a main route between Hanoi and Vientiane and was ringed by mountains. Operation Castor was launched on November 20, 1953, with 1,800 men of the French 1st and 2nd Airborne Battalions dropping into the valley of Điện Biên Phủ and sweeping aside the local Việt Minh garrison. The paratroopers gained control of a heart-shaped valley 12 miles (19 km) long and 8 miles (13 km) wide surrounded by heavily wooded mountains. Encountering little opposition, the French and Tai units operating from Lai Châu to the north patrolled the mountains. The operation was a tactical success for the French.

Sources: en.wikipedia.org

Further detail

(2002) subsequently confirmed the same model for hydrogen adsorption on magnesia-supported caesium-ruthenium bimetallic catalysts. Trens et al. (2009) have similarly described CO surface diffusion on carbon-supported Pt particles of varying morphology.

=== History === In 1989, Alan Mackay suggested that if chemical synthesis could be used to make L-protein and D-protein enantiomers, it would enable the use of racemic mixtures to crystallize proteins in centrosymmetric space groups. He stated that, because in the X-ray diffraction data obtained from a centrosymmetric crystal the off-diagonal phases would cancel giving phases that differ by 180 degrees, this would facilitate solving the phase problem in protein structure determination through X-ray crystallography. In 1993, Laura Zawadzke and Jeremy Berg first used the small (45 amino acids) protein rubredoxin to synthesize it in racemic form. This was done since the structural determination would potentially be easier and more robust by using diffraction data from a centrosymmetric crystal, which requires growth from a racemic mixture. By having a centre of symmetry formed by the racemic protein pairs, the steps of phasing diffraction in data analysis would be further simplified. As mentioned above, in 1995 Stephanie Wukovitz and Todd Yeates developed a mathematical theory to explain why protein molecules tend to crystallize more frequently in certain space groups than in others; they predicted that the most favored protein space group would be P1<bar>, and predicted that globular proteins would crystallize more easily as racemates, from a racemic protein mixture.

== Food sources == Xanthophylls are found in all young leaves and in etiolated leaves. Examples of other rich sources include papaya, peaches, prunes, and squash, which contain lutein diesters. Kale contains about 18 mg lutein and zeaxanthin per 100g, spinach about 11 mg/100g, parsley about 6 mg/100g, peas about 3 mg/110g, squash about 2 mg/100g, and pistachios about 1 mg/100g.

People can be exposed to manganese (Mn) through inhalation of dust from mining, welding, smelting, or other occupational use, forest fires and volcanic eruptions, pollution in groundwater and air, ingesting contaminated food or water, and by taking illicit drugs cut with manganese. At very low levels, Mn is essential to healthy energy metabolism and antioxidant function. However, overexposure to Mn is neurotoxic. High levels of Mn interfere with mitochondrial respiration and cause oxidative stress and other effects. Mn overexposure leads to both motor and cognitive dysfunction, displaying similarities to symptoms of Parkinson's Disease. Similarities and differences between manganism (toxicity), manganese-related parkinsonism, and Parkinson's disease (neurodegenerative) are a matter of research and debate. Concentrations of Mn and timing of exposure (acute or chronic) may be related to different mechanisms, effects, and diagnosis. Acute exposure to high levels of Mn primarily affects the globus pallidus. Chronic lifetime exposure at low levels may affect brain areas more broadly, including the substantia nigra. A patient's occupational history is important for distinguishing cases of toxicity from neurodegenerative disease, and identifying appropriate treatment.

In the pharmaceutical industry, a blockbuster drug is one that achieves acceptance by prescribing physicians as a therapeutic standard for, most commonly, a highly prevalent chronic (rather than acute) condition. Patients often take the medicines for long periods.

Sources: en.wikipedia.org

Background from the literature

Artificial gene synthesis, or simply gene synthesis, refers to a group of methods that are used in synthetic biology to construct and assemble genes from nucleotides de novo. Unlike DNA synthesis in living cells, artificial gene synthesis does not require template DNA, allowing virtually any DNA sequence to be synthesized in the laboratory. It comprises two main steps, the first of which is solid-phase DNA synthesis, sometimes known as DNA printing. This produces oligonucleotide fragments that are generally under 200 base pairs. The second step then involves connecting these oligonucleotide fragments using various DNA assembly methods. Because artificial gene synthesis does not require template DNA, it is theoretically possible to make a completely synthetic DNA molecule with no limits on the nucleotide sequence or size. Synthesis of the first complete gene, a yeast tRNA, was demonstrated by Har Gobind Khorana and coworkers in 1972. Synthesis of the first peptide- and protein-coding genes was performed in the laboratories of Herbert Boyer and Alexander Markham, respectively. More recently, artificial gene synthesis methods have been developed that will allow the assembly of entire chromosomes and genomes. The first synthetic yeast chromosome was synthesised in 2014, and entire functional bacterial chromosomes have also been synthesised. In addition, artificial gene synthesis could in the future make use of novel nucleobase pairs (unnatural base pairs).

== Adverse effects == The adverse effects of pethidine administration are primarily those of the opioids as a class: nausea, vomiting, dizziness, diaphoresis, urinary retention, and constipation. Due to moderate stimulant effects mediated by pethidine's dopamine and norepinephrine reuptake inhibition, sedation is less likely compared to other opioids. Unlike other opioids, it does not cause miosis because of its anticholinergic properties. Overdose can cause muscle flaccidity, respiratory depression, obtundation, psychosis, cold and clammy skin, hypotension, and coma. A narcotic antagonist such as naloxone is indicated to reverse respiratory depression and other effects of pethidine. Serotonin syndrome has occurred in patients receiving concurrent antidepressant therapy with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors, or other medication types (see Interactions below). Convulsive seizures sometimes observed in patients receiving parenteral pethidine on a chronic basis have been attributed to accumulation in plasma of the metabolite norpethidine (normeperidine). Fatalities have occurred following either oral or intravenous pethidine overdose.

The oral bioavailability of amphetamine varies with gastrointestinal pH; it is well absorbed from the gut, and bioavailability is typically 90%. Amphetamine is a weak base with a pKa of 9.9; consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid-rich cell membranes of the gut epithelium. Conversely, an acidic pH means the drug is predominantly in a water-soluble cationic (salt) form, and less is absorbed. Between 16-20% of amphetamine circulating in the bloodstream is bound to plasma proteins. Following absorption, amphetamine readily distributes into most tissues in the body, with high concentrations occurring in cerebrospinal fluid and brain tissue. The half-lives of amphetamine enantiomers differ and vary with urine pH. At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are 9–11 hours and 11–14 hours, respectively. Highly acidic urine will reduce the enantiomer half-lives to 7 hours; highly alkaline urine will increase the half-lives up to 34 hours. The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3 hours and 7 hours post-dose respectively. Amphetamine is eliminated via the kidneys, with 30–40% of the drug being excreted unchanged at normal urinary pH. When the urinary pH is basic, amphetamine is in its free base form, so less is excreted.

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces an immediate psychological reward, despite substantial harm and other negative consequences. Repeated substance use produces long-lasting changes in brain networks involved in reward, executive function, stress reactivity and mood. These changes underlie both the intense drive to use a substance and the reduced capacity to control that urge. It is therefore understood as a brain disorder arising from a complex mix of psychosocial and neurobiological factors. A number of researchers argue that this framing is incomplete, and that addiction is better understood as learned behavior shaped by choice and social context. Addiction takes both substance and non-substance forms. Substance addictions include alcoholism, cannabis addiction, amphetamine addiction, cocaine addiction, nicotine addiction, and opioid addiction. The DSM-5-TR recognizes only gambling disorder as a behavioral (non-substance) addiction and lists internet gaming disorder as a condition for further study, while the ICD-11 additionally classifies gaming disorder as a disorder due to addictive behaviors. Other candidate behavioral addictions, and the question of whether food can be addictive, are debated in the research literature but are not recognized in either manual.

=== RNA interference === RNA interference (RNAi) uses segments of RNA to fatally silence crucial insect genes. In 2024 two uses of RNAi have been registered by the authorities for use: Genetic modification of a crop to introduce a gene coding for an RNAi fragment and spraying double stranded RNA fragments onto a field. Monsanto introduced the trait DvSnf7 which expresses a double-stranded RNA transcript containing a 240 bp fragment of the WCR Snf7 gene of the Western Corn Rootworm. GreenLight Biosciences introduced Ledprona, a formulation of double stranded RNA as a spray for potato fields. It targets the essential gene for proteasome subunit beta type-5 (PSMB5) in the Colorado potato beetle.

Sources: en.wikipedia.org

Frequently asked questions

Is this peptide found naturally in the body?

Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.

Why is the disulfide bridge important?

The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.

How does it differ from other thymic peptides?

It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Network